Office of Biomedical Professors, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710, Korea.
Immune Netw. 2012 Apr;12(2):66-9. doi: 10.4110/in.2012.12.2.66. Epub 2012 Apr 30.
The immunological death induction by EY-6 on the human tumor cell lines was screened. Human colon carcinoma (HCT15, HCT116), gastric carcinoma (MKN74, SNU668), and myeloma (KMS20, KMS26, KMS34) cells were died by EY-6 treatment with dose-dependent manner. CRT expression, a typical marker for the immunological death, was increased on the EY-6-treated colorectal and gastric cancer cells. Interestingly, the effects on the myeloma cell lines were complicated showing cell line dependent differential modulation. Cytokine secretion from the EY-6 treated tumor cells were dose and cell-dependent. IFN-γ and IL-12 secretion was increased in the treated cells (200% to over 1000% of non-treated control), except HCT116, SNU668 and KMS26 cells which their secretion was declined by EY-6. Data suggest the potential of EY-6 as a new type of immuno-chemotherapeutics inducing tumor-specific cell death. Further studies are planned to confirm the efficacy of EY-6 including in vivo study.
对 EY-6 诱导人肿瘤细胞系免疫性死亡进行了筛选。人结肠癌细胞（HCT15、HCT116）、胃癌细胞（MKN74、SNU668）和骨髓瘤细胞（KMS20、KMS26、KMS34）均呈现剂量依赖性死亡。CRT 表达是免疫性死亡的典型标志物，在 EY-6 处理的结直肠和胃癌细胞中增加。有趣的是，骨髓瘤细胞系的作用较为复杂，呈现出细胞系依赖性的差异调节。细胞因子从 EY-6 处理的肿瘤细胞中的分泌具有剂量和细胞依赖性。IFN-γ和 IL-12 的分泌在处理细胞中增加（非处理对照的 200%至 1000%以上），但 HCT116、SNU668 和 KMS26 细胞除外，其分泌被 EY-6 下调。数据表明 EY-6 作为一种诱导肿瘤特异性细胞死亡的新型免疫化疗药物具有潜力。计划进一步研究以确认 EY-6 的疗效，包括体内研究。
